spacer
home > ict > autumn 2016 > communication is key
PUBLICATIONS
International Clinical Trials

Communication is Key

ICT: This year’s spotlight at the Partnerships in Clinical Trials (PCT) Europe event is on patient centricity. In your opinion, what are the main challenges in recruiting and retaining subjects today, and what can be done to improve this often labour-intensive and costly task?

Naomi Brooker: While researching with industry professionals, it appears that one of the fundamental issues lies within how we are communicating – patients don’t want to feel like guinea pigs that are being experimented on. The general public perception is that clinical trials can be risky, and this can be off-putting; after all, they generally only see the disasters in the news, not the many success stories that arise from trials. In particular, some patients worry that they could be given a placebo that could be detrimental to their health, while others are concerned that companies are more interested in profit than helping them recover; others decided that the risk factor was too great.

To remove this underlying fear, communication is key and marketing campaigns, as well as patient advocates, can play a pivotal role. What are you, as a company, doing to ensure that patients feel valued? How are they engaged with? Are they treated as a number or a person? These are the real questions that can make a difference.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Naomi Brooker is the Conference Director of PCT Europe, developing the event in partnership with their advisory board. Since completing a BSc at UCL, UK, in Biomedical Science and a Law Conversion at BBP Law School, UK, she has been researching key trends and current challenges with various industry sectors such as pharma and agrochemical, most recently focusing on clinical trials.
spacer
Naomi Brooker
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

First own Gerresheimer Autoinjector - Gerresheimer and Midas Pharma announce strategic partnership

– Gerresheimer’s first own IP autoinjector suitable for both small and large molecules enhances broad portfolio of solutions, medical devices and pharmaceutical primary packaging – First joint project of Gerresheimer and Midas Pharma: Development and marketing of new autoinjector – One-stop-shop for biotech and pharma customers Duesseldorf, November 08, 2021 – Gerresheimer acquired the IP of a new generation cartridge based autoinjector from Midas Pharma. This is the start of a strategic partnership. The joint project comprises the development and marketing of the new generation autoinjector.
More info >>

White Papers

New Temperature Profiles from a Global Study

Laminar Medica

Recently there has been an influx of temperature mapping studies to collect sufficient ambient data to develop temperature profiles.  Solid temperature profiles on specific shipping routes are required to ensure streamlined packaging and robust lane qualification. The most reliable method to develop temperature profiles is to capture the actual reading from shipments, as well as using the historical and meteorological data to increase the confidence level.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement